WO2009062128A3 - Combination drug therapy for the treatment of cancer - Google Patents
Combination drug therapy for the treatment of cancer Download PDFInfo
- Publication number
- WO2009062128A3 WO2009062128A3 PCT/US2008/082924 US2008082924W WO2009062128A3 WO 2009062128 A3 WO2009062128 A3 WO 2009062128A3 US 2008082924 W US2008082924 W US 2008082924W WO 2009062128 A3 WO2009062128 A3 WO 2009062128A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- drug therapy
- cancer
- combination drug
- combination
- inhibits
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
A combination of drugs was used to kill or inhibit the growth of cancer cells. The combination drug therapy includes administering to a human or animal patient diagnosed with cancer at least one drug that inhibits the activity of an intracellular protein that repairs alkylated DNA and a drug that inhibits the interaction between Hdm2 and p53. The combination drug therapy is useful in the treatment of tumors including some tumors that have become drug resistant. In some instances the combination drug therapy allows the drugs to be administered to a patient at therapeutically effective submyeloablative levels. Still another aspect provides a combination drug therapy that includes administering to a cancer patient a therapeutically effective dose of at least one compound that alkylates DNA, at least one compound that inhibits at least one DNA repair protein and at least one compound that prolongs the half-life of p53 by inhibiting the interaction of p53 with HDM2.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US98652507P | 2007-11-08 | 2007-11-08 | |
US60/986,525 | 2007-11-08 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2009062128A2 WO2009062128A2 (en) | 2009-05-14 |
WO2009062128A3 true WO2009062128A3 (en) | 2009-09-17 |
Family
ID=40626463
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2008/082924 WO2009062128A2 (en) | 2007-11-08 | 2008-11-08 | Combination drug therapy for the treatment of cancer |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2009062128A2 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL2981279T3 (en) | 2013-04-05 | 2019-09-30 | Biomarck Pharmaceuticals Ltd. | Marcks inhibitor peptides for inhibiting metastasis |
CN104174020A (en) * | 2013-05-21 | 2014-12-03 | 北京大学 | Application of human derived protein hCINAP and its gene in development of anticancer drugs |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060211757A1 (en) * | 2005-02-22 | 2006-09-21 | Regents Of The University Of Michigan | Small molecule inhibitors of MDM2 and the uses thereof |
-
2008
- 2008-11-08 WO PCT/US2008/082924 patent/WO2009062128A2/en active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060211757A1 (en) * | 2005-02-22 | 2006-09-21 | Regents Of The University Of Michigan | Small molecule inhibitors of MDM2 and the uses thereof |
Non-Patent Citations (6)
Also Published As
Publication number | Publication date |
---|---|
WO2009062128A2 (en) | 2009-05-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1778215B1 (en) | Anticancer effect enhancer | |
BRPI0510895A (en) | 10-propargyl-10-deazaaminopterin pharmaceutical formulation for t-cell lymphoma treatment | |
American Society of Anesthesiologists Task Force on Perioperative Management of Patients with Cardiac Rhythm Management Devices | Practice advisory for the perioperative management of patients with cardiac rhythm management devices: pacemakers and implantable cardioverter-defibrillators: a report by the American Society of Anesthesiologists Task Force on Perioperative Management of Patients with Cardiac Rhythm Management Devices | |
WO2004062604A3 (en) | Treatment of cancer with 2-deoxyglucose | |
ECSP056076A (en) | SUPPLY SYSTEM FOR DRUG AND CELL THERAPY | |
MX2007012817A (en) | Elimination of heterogeneous or mixed cell population in tumors. | |
AU2013308465B2 (en) | Drug delivery systems and methods for treatment of prostate disease comprising gemicitabine | |
BRPI0519656A2 (en) | combination therapy comprising telmisartan and hydrochlorothiazide | |
MX2012000275A (en) | Acid pump antagonist for treatment of diseases associated with abnormal gastrointestinal movement. | |
BR112013010829A2 (en) | intravenous pharmaceutical composition to provide pain and / or inflammation relief, use and method thereof | |
RU2012108439A (en) | METHODS FOR TREATING TUMORS OF THE BRAIN | |
TNSN07474A1 (en) | Dosage regimen for prasugrel | |
CY1118486T1 (en) | LAPATINIBE FOR CANCER TREATMENT | |
DE602004016376D1 (en) | COMBINATION OF ET-743 WITH 5-FLUOROURACIL PRO DRUGS FOR THE TREATMENT OF CANCER | |
AR079000A1 (en) | ANTI-BANK THERAPY AIMED AT CANCEROSA MOTHER RESISTANT DRUG CELLS | |
Holliday et al. | Methotrexate: role of treatment in skin disease | |
WO2009062128A3 (en) | Combination drug therapy for the treatment of cancer | |
Hu et al. | Weekly paclitaxel with concurrent radiotherapy followed by adjuvant chemotherapy in locally advanced nasopharyngeal carcinoma | |
Blakley et al. | Differences in Ototoxicity across Species. | |
US20110250291A1 (en) | Use of arsenic for cancer therapy protection | |
Murata et al. | Enhanced local tumour control after single or fractionated radiation treatment using the hypoxic cell radiosensitizer doranidazole | |
WO2001080895A3 (en) | Methods and compositions for the treatment of cardiac indications | |
MX2010006310A (en) | O-desmethyl-venlafaxine for treating major depressive disorder. | |
ES2543364B1 (en) | PHARMACEUTICAL COMPOSITION UNDERSTANDING THE COMBINATION OF AN NON-STEROID ANTI-INFLAMMATORY AGENT, AN ADJUSING AGENT AND AN ANTI-NURETIC ANALGESIC, WITH ANTI-BIOCEPTIVE EFFECT | |
RU2007141393A (en) | METHOD FOR TREATING SPASTIC AND PAIN SYNDROMES IN PATIENTS WITH CONSEQUENCES OF SPIN AND SPIN INJURY |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08847359 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 08847359 Country of ref document: EP Kind code of ref document: A2 |